


Data Sheet

Product Name:	GSK3145095
Cat. No.:	CS-0094287
CAS No.:	1622849-43-7
Molecular Formula:	C ₂₀ H ₁₇ F ₂ N ₅ O ₂
Molecular Weight:	397.38
Target:	RIP kinase
Pathway:	Apoptosis
Solubility:	DMSO : 250 mg/mL (629.12 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

GSK3145095 is a **RIP1 kinase** inhibitor with an **IC₅₀** of 6.3 nM ^[1]. IC₅₀ & Target: IC₅₀: 6.3 nM (RIP1 kinase) ^[1] **In Vitro:** GSK3145095 potently blocks the TNF response as shown by determination of overall cell viability as measured by cellular ATP levels (IC₅₀ = 1.6 nM), cell death as measured by LDH release (IC₅₀ = 0.5 nM) and RIP1-dependent inflammatory cytokine MIP-1 β production, either as absolute levels for protein, or fold changes in mRNA expression (IC₅₀ = 0.4 nM) ^[1].

References:

[1]. Harris PA, ET AL. Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.

CAIndexNames:

1H-1,2,4-Triazole-5-carboxamide, N-[(3S)-7,9-difluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-3-(phenylmethyl)-

SMILES:

FC1=CC(F)=CC2=C1NC([C@@H](NC(C3=NNC(CC4=CC=CC=C4)=N3)=O)CC2)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA